Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

those in before today's hike should consider selling and buying back later!!! :-))))

WH Ireland note:
"ANGLE has announced that its 85% owned US-based portfolio company, Parsortix Inc. has completed a study demonstrating that its cell separation device reproducibly isolates and captures tumour cells in cancer patient blood, and emphasises that the cancer cells can be identified within the device without requiring a complicated cell extraction process. These are highly promising findings, which ANGLE believes give the technology an immediate market application in cancer research enabling sales of the product for research purposes from the second half of 2012.
Following this, the next step is to replicate these results in larger clinical trials to obtain US and European regulatory marketing approvals, which would enable Parsortix Inc. to sell the technology as a cost-effective, non-invasive, reliable screening tool to improve cancer treatment through early detection of cancer and monitoring of cancer patients while receiving treatment and those in remission. ANGLE estimates that the addressable clinical market for a simple circulating tumour cells counting device in the US alone exceeds $4 billion per annum."

one for the future here when sp reverses

gibby

re - those in before today's hike should consider selling and buying back later!!! :-))))


The time is not right for taking profits, I would say it has to go much much higher than the 56p at the time of you comment, think about a price close to 100p, though 85p could be a difficult price to go over

A lovely intraday UP trend, only falling a bit at 4pm after steady pause, as the profit takers (trades ) were busy cashing in for the day.

expect good comments on the press tomorrow and brokers making new updates

from ...growth company

ANGLE soars on cancer breakthrough
28/09/2011 Robert Tyerman

Shares in intellectual property backer ANGLE (AGL) have doubled on successful cancer cell separation by its US diagnostics company, Parsortix.

Guildford-based ANGLE says Parsortix, of which it owns 85 per cent, has 'validated' that its patented cell separation device can capture cancer cells added to blood.

AIM-quoted ANGLE says this device can be used, on a reproducible basis, to 'isolate and capture very small numbers of cancer cells from whole blood'. The company declares that the device 'appears to capture efficiently all of the cancer cells, avoiding the risk of failing to detect cancer cells in a blood sample' and 'allows the identification of cancer cells within the device, without requiring a complicated cell extraction process'.

ANGLE contends that the Parsortix device has immediate market application for research and says it has started talking to 'several of the world's leading cancer research institutes', with the aim of selling the product for research as early as the second half of next year. The company adds that it has also opened discussions about collaborating with major global diagnostic concerns.

Beyond this lies the possibility of selling a product direct, subject to key regulatory approvals, and targeting the blood test market, estimated to be worth more than 2.5 billion in the USA alone. ANGLE says its target is to seek approval from the US Food and Drug Administration and the European authorities by mid-2013, allowing commercial sales for cancer detection, cancer patient monitoring and post-treatment monitoring.

Andew Newland, founder, chief executive and substantial ANGLE shareholder, says Parsortix's cancer diagnostic 'offers an outstanding commercial opportunity'. Investors agree and have sent the shares, highlighted by Growth Company Investor in July at 27p, up 28.25p today to 56.25p, valuing the company at nearly 20 million.

Hold on for now.

ANGLE soars on cancer breakthrough

Proactive investors

In the meantime, todays big news from Angle (LON:AGL) went somewhat unnoticed, buried under the pile of reported from the oil and gas sector.

However, the company emerged among the most actively discussed stocks on message boards after seeing its share price double on the announcement that its 85 percent owned company Parsortix has validated that its cell separation device can capture cancer cells added to blood.

The group has already entered discussions with what it said were several of the world's leading cancer research institutes and reported strong interest in such a product, which would require regulatory approval for use for research purposes.

Angle is targeting to sell the product for research purposes as early as the second half of 2012.

We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angles commercial opportunity...by this point, we would anticipate Parsortix to have attracted commercial interest from majors, said analysts at Collins Stewart.

The broker currently has a target price of 44 pence for the stock, however, it may want to update it after the companys share price rose from 28 pence to 56 pence this afternoon.

However, Collins Stewart noted in todays report that its valuation only presently ascribes partial value to 1 venture. The broker added that the success of any of the opportunities in its venture portfolio would highlight significant upside optionality in the Groups current share price.

Many investors following Angle agreed, noting that even after the increase, the company still has a market cap of 20 million, which, in their opinion, does not reflect the commercial potential of Parsortix.

http://www.proactiveinvestors.co.uk/companies/news/33689/wednesdays-most-followed-man-group-red-emperor-resources-dominos-pizza-angle-plc-33689.html

hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider

anyhow - there were several reasons for that note because the buys were virtually all small p.i.s who followed the crowd - no major ii at all - some trades that have not been shown yet and the fact nobody really understands the significance - also the product only appears to capture on cancer cells NOT does capture all - the market for this is huge but this treatment if after 2013 actually works will only capture a % of this not all of it - and other major players out there - i still say seriously consider cashing in but weigh up all options and watch very closely before jumping out if anyone does - iis will not be interested at this price - that is the city chatter - will wait for the euphoria and sp to reverse maybe move a month or two down when everyone chasing other quick wins

serious well done to any in before the hike today and those who have taken a risk and have already got out at profit - and good lick if they are trying for more profit tomorrow by hanging on - pre-open tomorrow should be very interesting - will it be another + 100% tomorrow or -50%?

btw the target sp for this a few years ago has been in or around 170p - since then dilution and many more shares in circulation - consider all factors particulary ii take

one thing is for sure - this was serious good news today - may keep the sp up and some more north tomorrow but only in the short term imo

just looked at this - poor inexperienced sods early this morning who paid far too much - price is still to high dont get locked in imo

gla

Thanks for that gibby.

do not thank too early, it went to 79p this morning, and with a market well down, you have to expect taders taking profits.

is now on the way up again, and looks strong enough to go places

AGL
Newspapers Guardian .........

But the day's standout performer was Aim-listed Angle, up 129% to 64.25p after it said a cell separation device from its Parsortix division could be used to isolate and capture very small numbers of cancer cells from blood. It is in discussions about the device with a number of cancer research institutes. Collins Stewart said:

We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angle's commercial opportunity. Parsortix is aiming to seek both FDA approval and European CE mark accreditation by mid 2013. Such approvals would open up multi billion dollar clinical markets including cancer detection and monitoring, in addition to the immediate market available for research purposes. By this point, we would anticipate Parsortix to have attracted commercial interest from majors.

guardian
----------------
Technology firm Angle has announced that Parsortix, its 85% owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.

Parsortix's patented cell separation device can be used, on a reproducible basis, to isolate and capture very small numbers of cancer cells from whole blood, Angle reports.

The device appears to efficiently capture all of the cancer cells, avoiding the risk of failing to detect cancer cells present in a blood sample.

It allows the identification of cancer cells within the device, without requiring a complicated cell extraction process and does not require the use of expensive and sometimes unreliable antibody affinity capture technology to isolate the cancer cells.

Angle said: "The company has already established discussions with several of the world's leading cancer research institutes and there is strong interest in such a product, which would not require regulatory approval for use for research purposes. The target is to establish sales of the product for research purposes as early as the second half of 2012.

"There is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies and initial discussions have identified encouraging interest in a commercial collaboration. This will be explored further over the coming months."

The group added: "There are major clinical markets for a simple CTC [circulating tumour cells] counting product estimated to exceed $4 bn per annum in the United States market alone. The target is to seek FDA [Food and Drug Administration] approval and European CE Mark by mid 2013 enabling sales of product for clinical use."

The CE mark is a mandatory conformity mark for products marketed in the European Union.

livecharts - Angle-announces-new-cancer-detection-device-
--------------
The junior AIM market provided the major fireworks with shares of technology firm Angle soaring to an all-time high of 66p before closing 36.25p or 129 per cent higher at 64.25p. Buyers piled in on hearing that Parsortix, its 85 per cent owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.

Angle has already had discussions with several of the world cancer research institutes and there is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies.

Read more: this is money - MARKET-REPORT

Good call gibby

re - dreamcatcher - 29 Sep 2011 11:44 - 88 of 88
Good call gibby


I wonder if you follow the stock, sell at 56p and missed of the way to 79p

re - gibby - 28 Sep 2011 21:02 - 82 of 88
hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider


that is not what you said, just read it again and stop to cover you bad sugestion.
Any stock with a large rise and large volume will have another day of rise if is two before profit taking is recomended. On small stocks is very difficult to sell and buy back on the same day as MMs use tricks and large spreads, many try it yesterday and had to pay higher price.

gibby - 28 Sep 2011 12:51 - 75 of 91
re - those in before today's hike should consider selling and buying back later!!! :-))))

Machoman its a very good stock. Wish I did have it. gl

lol macho - i said consider sell to buy back not sell read it again - you twisted my words a tad there :-))

however today's low was 51p - high 70 odd pence - i think that speaks for itself - btw

you wont have any problem buying if quick enough

this for me now is one for the future more 2013 before seeing real increases to 3 figures here

pharma is not a cheap industry more funds will be needed and notoriously slow

momentum from p.i.s is all thats left for now here until further news imo

anyhow people could have top sliced remember

hi dc - seen similar to agl many time - even in recent times such as pym / phytopharm, pyc, sar etc - it will happen again

nothing wrong with agl but needs a reality check

hope you are having a good day

gibby

There is no LOL but BAD recomendation from you, you can twisted and turn it 1 million
times. ( if you do not sell how are you going to buy back )

The proof is on the pudding
at the time of saying it was 56p and went this morning to 79p.

re - however today's low was 51p

Your nonsence goes further as you do not know lows and highs of the day also
Missed this morning 23p ( 79 - 56p ) I gain 23p
retracement to 52p this morning you gain 4p ( if you say is time to buy back low of the day)

Just tell me who is right?